Patterns and Gaps Identified in a Systematic Review of the Hepatitis C Virus Care Continuum in Studies among People Who Use Drugs

被引:15
作者
Jordan, Ashly E. [1 ,2 ]
Perlman, David C. [2 ,3 ]
Reed, Jennifer [1 ]
Smith, Daniel J. [1 ]
Hagan, Holly [1 ,2 ]
机构
[1] NYU, Rory Meyers Coll Nursing, 550 1St Ave, New York, NY 10003 USA
[2] Ctr Drug Use & HIV Res New York, New York, NY 10010 USA
[3] Icahn Sch Med, Mt Sinai Beth Israel, New York, NY USA
基金
美国国家卫生研究院;
关键词
people who use drugs; hepatitis C virus infection; hepatitis C virus care continuum; systematic review; evidence base; GLOBAL BURDEN; INFECTION; HEALTH; DISEASE; POLICY;
D O I
10.3389/fpubh.2017.00348
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Introduction: Systematic reviews are useful for synthesizing data on various health conditions and for identifying gaps in available data. In the US, the main risk group for hepatitis C virus (HCV) infection is people who use drugs (PWUD); as a group, PWUD have the highest prevalence of chronic HCV. While the care continuum construct has been increasingly applied to studies of HCV care among PWUD, what constitutes the steps in an HCV care continuum is not standardized. We sought to examine the range of HCV care continuum outcomes that studies reported on, to identify gaps in the literature, and to develop strategies that allowed for valuable syntheses of care continuum data. Methods: We conducted searches of electronic databases for published literature. Reports were eligible if they provided original data from 1990 to 2016 from the US, presented data on one or more HCV care continuum outcomes, and provided outcome data on PWUD as a distinct group. Results: A total of 313 full-text reports were assessed for eligibility. Of 212 potentially eligible reports, 32 (15.1%) did not present outcomes for PWUD separately from those who were non-PWUD. Among 101 eligible reports, a total of 166 care continuum outcomes were extracted; outcomes could be grouped into three categories that represent the HCV care continuum: testing (39.8%, n = 66/166); linkage to care (16.9%, n = 28/166); and treatment (43.4%, n = 72/166). Seventy-four reports (73.3%, n =74/101) presented data on only one step. Linkage to care occurred variably after only antibody, or after antibody and viral load (VL) testing. Six (5.9%, n = 6/101) reports presented data on all three steps. Conclusion: Reports examined a variety of HCV care continuum outcomes that could be grouped into the three steps of testing, linkage to care, and treatment. The application of this care continuum model would facilitate subsequent data synthesis for program comparison and public health evaluation. Given the two-step nature of HCV testing, analyses also need to account for variation in whether linkage to care occurred after antibody testing or after sequential antibody and VL testing. Additional data are needed on the progression of PWUD through the entire care continuum.
引用
收藏
页数:7
相关论文
共 37 条
  • [1] AASLD/IDSA/IAS USA, 2017, REC TEST MAN TREAT H
  • [2] [Anonymous], 2012, Prioritizing future research through examination of research gaps in systematic reviews, DOI DOI 10.1016/j.jclinepi.2012.04.002
  • [3] [Anonymous], 2017, TRANSPARENT REPORTIN
  • [4] Treatment of Hepatitis C Virus Infection Among People Who Are Actively Injecting Drugs: A Systematic Review and Meta-analysis
    Aspinall, Esther J.
    Corson, Stephen
    Doyle, Joseph S.
    Grebely, Jason
    Hutchinson, Sharon J.
    Dore, Gregory J.
    Goldberg, David J.
    Hellard, Margaret E.
    [J]. CLINICAL INFECTIOUS DISEASES, 2013, 57 : S80 - S89
  • [5] Centers for Disease Control and Prevention, 2014, UND CAR CONT
  • [6] Scoping reviews: time for clarity in definition, methods, and reporting
    Colquhoun, Heather L.
    Levac, Danielle
    O'Brien, Kelly K.
    Straus, Sharon
    Tricco, Andrea C.
    Perrier, Laure
    Kastner, Monika
    Moher, David
    [J]. JOURNAL OF CLINICAL EPIDEMIOLOGY, 2014, 67 (12) : 1291 - 1294
  • [7] Estimating the burden of disease attributable to injecting drug use as a risk factor for HIV, hepatitis C, and hepatitis B: findings from the Global Burden of Disease Study 2013
    Degenhardt, Louisa
    Charlson, Fiona
    Stanaway, Jeff
    Lamey, Sarah
    Alexander, Lily T.
    Hickman, Matthew
    Cowie, Benjamin
    Hall, Wayne D.
    Strang, John
    Whiteford, Harvey
    Vos, Theo
    [J]. LANCET INFECTIOUS DISEASES, 2016, 16 (12) : 1385 - 1398
  • [8] Estarli M., 2016, Revista Espaola de Nutricin Humana y Diettica, V20, P148, DOI [https://doi.org/10.14306/renhyd.20.2.223, DOI 10.14306/RENHYD.20.2.223, 10.1186/2046-4053-4-1, 10.1186/s13643-015-0163-7, DOI 10.1186/S13643-015-0163-7]
  • [9] Why don't we see more translation of health promotion research to practice? Rethinking the efficacy-to- effectiveness transition
    Glasgow, RE
    Lichtenstein, E
    Marcus, AC
    [J]. AMERICAN JOURNAL OF PUBLIC HEALTH, 2003, 93 (08) : 1261 - 1267
  • [10] Eligibility for treatment of hepatitis C virus infection among young injection drug users in 3 US cities
    Hagan, H
    Latka, MH
    Campbell, JV
    Golub, ET
    Garfein, RS
    Thomas, DA
    Kapadia, F
    Strathdee, SA
    [J]. CLINICAL INFECTIOUS DISEASES, 2006, 42 (05) : 669 - 672